Off-market insider buying at Medexus Pharmaceuticals (V:MDP)

Peter van der Velden, a Director, acquired 1,463 Common Shares on an indirect ownership basis for registered holder Lumira Capital IV (International) L.P. and 54,438 Common Shares on an indirect ownership basis for registered holder Lumira Capital IV, L.P. at a price of $3.220 through a prospectus or prospectus exempt offering on September 30th, 2021. This represents a $180,001 investment into the company's shares and an account share holdings change of 14.9%.

Two other insiders also reported buying in smaller amounts.

Medexus Pharmaceuticals is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Medexus Pharmaceuticals Inc. is a Canada-based rare disease pharmaceutical company. The Company is a North American focused, specialty pharmaceutical business that operates through two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada, a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. Medexus Pharma USA, a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States (U.S). The Company is focused on the therapeutic areas of auto-immune disease, hematology, pediatrics, dermatology and allergy. The Company's products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases. It also offers IXINITY, a medicine for use in patients 12 years of age or older with Hemophilia B and Rupall, an allergy medication. Medexus Pharmaceuticals Inc. (MDP) has a high amount of executive buying compared to its micro-cap peers in the market over the past three months. According to regulatory filings yesterday, three insiders have invested a total amount of $187,385.